Скачать или смотреть BioVerse Episode 15 - M&A, The Ultimate Exit of Biotechs

Spkeakers:
Rachel Zimet Strick, MBA; VP of BD Transaction & Acquisition from AbbVie
Dandan Dong, PhD; Venture Partners from TCGX
Lihua Zheng, PhD, JD; CEO & Co-Founder of Z-Star Therapeutics
Tess Cameron, Principal of RA Capital

Moderator:
Nora Luo, IP Attorney of Jones Day
Leon Tang, Founder and Partner of InScienceWeTrust BioAdvisory

In this video:
00:00 Introduction of BioVerse
03:46 Introduction of the speakers
08:52 Tess provides an overview of the seasonality nature of the M&A market.
14:33 Rachel Strick provided a summary of the current M&A market from a buy-side biopharma's perspective.
24:03 Are biotechs sold or bought?
30:26 The hot therapy areas, modalities, or MoA in the current M&A market.
37:02 Rachel shares her buy-side view on the features of attractive acquisition targets.
39:55 Dandan provides insights from the views of an investor, company co-founder, and company builder.
44:25: Lihua provides his experience from his recent M&A between AnHearts and Nuvation Bio.
52:40: Tess shares high-level learning from the acquisitions of Mariana Oncology and Aliada Therapeutics.
56:26: Forecast of the 2025 M&A market from macro and policy perspectives.
59:35: Forecast of the China outbound deals in 2025 and beyond.
1:15:30: Closing remark and announcement of the future episodes.

We covered topics such as the number and value of transactions in 2024 compared to 2023, key features of 2024 M&A transactions, and the driving factors behind these trends. The webinar will also include insights from industry experts on the implications of the statement "companies are bought, not sold," recent experiences as a buyer, challenges in executing M&A strategies, and predictions for the M&A market in 2025.

Mingle with other attendees on our LinkedIn page here:   / attendees